Huang R, He H, Xu X, Lin X, et al. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer 2024 Mar 12. doi: 10.1002/cncr.35278.
PMID: 38470375